Compare UDR & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UDR | FMS |
|---|---|---|
| Founded | 1972 | 1996 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Misc Health and Biotechnology Services |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.9B | 14.1B |
| IPO Year | N/A | 1996 |
| Metric | UDR | FMS |
|---|---|---|
| Price | $35.32 | $23.27 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 13 | 2 |
| Target Price | ★ $40.12 | $30.00 |
| AVG Volume (30 Days) | ★ 2.6M | 482.1K |
| Earning Date | 10-29-2025 | 11-04-2025 |
| Dividend Yield | ★ 4.89% | 2.45% |
| EPS Growth | ★ 17.52 | 8.62 |
| EPS | 0.44 | ★ 2.86 |
| Revenue | $1,742,477,000.00 | ★ $23,046,819,198.00 |
| Revenue This Year | $1.17 | $2.12 |
| Revenue Next Year | $3.37 | $2.92 |
| P/E Ratio | $80.26 | ★ $15.86 |
| Revenue Growth | ★ 3.86 | 2.10 |
| 52 Week Low | $32.94 | $22.05 |
| 52 Week High | $46.47 | $30.46 |
| Indicator | UDR | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 46.52 | 37.10 |
| Support Level | $34.21 | $22.51 |
| Resistance Level | $36.52 | $24.20 |
| Average True Range (ATR) | 0.60 | 0.30 |
| MACD | 0.06 | 0.09 |
| Stochastic Oscillator | 40.47 | 45.27 |
UDR Inc is a real estate investment trust that owns, operates, acquires, renovates, develops, redevelops, disposes of, and manages multifamily apartment communities in targeted markets located in the United States. The company has two reportable segments; Same-Store Communities segment represents those communities acquired, developed, and stabilized; and Non-Mature Communities/Other segment represents those communities that do not meet the criteria to be included in Same-Store Communities, including, but not limited to, recently acquired, developed and redeveloped communities, and the non-apartment components of mixed-use properties. It generates key revenue from Same-Store Communities.
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.